Australia markets closed

Virios Therapeutics, Inc. (VIRI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.56-0.09 (-1.35%)
At close: 04:00PM EST
6.63 +0.07 (+1.07%)
After hours: 04:18PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 39.49M
Enterprise value 43.21M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.09
Enterprise value/revenue N/A
Enterprise value/EBITDA -2.42

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-15.79%
S&P500 52-week change 314.07%
52-week high 38.79
52-week low 34.00
50-day moving average 35.42
200-day moving average 35.45

Share statistics

Avg vol (3-month) 334.29k
Avg vol (10-day) 330.8k
Shares outstanding 58.33M
Implied shares outstanding 6N/A
Float 86.71M
% held by insiders 110.90%
% held by institutions 111.47%
Shares short (30 Dec 2021) 464.84k
Short ratio (30 Dec 2021) 42.18
Short % of float (30 Dec 2021) 40.98%
Short % of shares outstanding (30 Dec 2021) 40.78%
Shares short (prior month 29 Nov 2021) 479.74k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-106.95%
Return on equity (ttm)-261.46%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-17.95M
Diluted EPS (ttm)-2.38
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)19.19M
Total cash per share (mrq)2.3
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)16.39
Book value per share (mrq)2.27

Cash flow statement

Operating cash flow (ttm)-12.8M
Levered free cash flow (ttm)-7.01M